Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: A noninvasive colorimetric assessment

Valeria Brazzelli, Elena Roveda, Francesca Prestinari, Tania Barbagallo, Eleonora Bellani, Valentina Trevisan, Claudia Rona, Franco Locatelli, Marco Zecca, Giovanni Borroni

Research output: Contribution to journalArticle

Abstract

Imatinib mesylate is a drug that has been recently approved for the treatment for chronic myeloid leukemia. It acts as a potent and selective inhibitor of BCR-ABL tyrosine kinase. It also inhibits both c-kit and platelet-derived growth factor receptor tyrosine kinases. Hypopigmentation of the skin in patients receiving this drug has been recently reported. We report a 17-year-old Caucasian patient affected by chronic myeloid leukemia in therapy with imatinib mesylate who developed hypopigmented vitiligo-like patches and generalized lightening of the skin. In order to evaluate the lightening observed clinically, we measured the progressive skin color hypopigmentation by using a colorimeter over several months. The colorimetric evaluation confirmed the generalized and gradual lightening of patient's skin over treatment with imatinib mesylate. We believe that this is the first reported instance of vitiligo-like lesions in a pediatric patient treated with imatinib mesylate, and the second in a Caucasian patient.

Original languageEnglish
Pages (from-to)175-178
Number of pages4
JournalPediatric Dermatology
Volume23
Issue number2
DOIs
Publication statusPublished - Mar 2006

ASJC Scopus subject areas

  • Dermatology
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: A noninvasive colorimetric assessment'. Together they form a unique fingerprint.

  • Cite this